Fenix, you are absolutely right.  By its very nature, the medical profession has to be skeptical of any claims until the trial data shows results.  

And I am with you on the complexity of the human body.

In the case of RVX however, I feel less concerned.  As I explained, safety is not an issue, at least from everything I have read.  Then the efficacy of the molecule is tantalizing in the various reports that have come out.  I look at eGFR data, and think that alone can generate a $1 billion/year drug.  

But more generally, if Apabetalone downregulates 8 of 11 pro-atherogenic genes and upregulates 5 of 7 anti-atherogenic genes that control monocyte recruitment, migration and activation, macrophage function, inflammatory signalling and plaque stability...that is more than enough for me to become a believer.